Table 1.
Patient characteristics.
| Variable | Global series (N = 413) | Transplant-eligible (N = 228) | Transplant-ineligible (N = 149) | Asymptomatic (N = 36) |
|---|---|---|---|---|
| Sex | ||||
| Men | 54.5% | 62.1% | 45.8% | 54.8% |
| Women | 45.5% | 37.9% | 54.2% | 45.2% |
| Age | 64 years (37−91) | 59 years (37−69) | 72 years (48−91) | 60 years (42−77) |
| IgH | ||||
| IgG | 59.4% | 55.8% | 62.8% | 42.3% |
| IgA | 32.8% | 35.5% | 30.4% | 50% |
| Bence−Jones | 6.9% | 7.0% | 6.8% | 7.7% |
| Nonsecretory | 0.9% | 1.7% | 0% | 0% |
| IgL | ||||
| Kappa chain | 62.5% | 63.5% | 60.7% | 50% |
| Lambda chain | 37.5% | 36.5% | 39.3% | 50% |
| Calcium | 9.63 ± 1.72 mg/dL (0.45−17) | 9.50 ± 1.99 mg/dL (0.45−17) | 9.78 ± 1.37 mg/dL (2.28−14.4) | 9.11 ± 0.49 mg/dL (8−10) |
| Creatinine | 1.16 ± 0.84 mg/dL (0.20−6.50) | 1.11 ± 0.76 mg/dL (0.20−6.50) | 1.21 ± 0.93 mg/dL (0.36−5.90) | 0.89 ± 0.28 mg/dL (0.50−1.61) |
| Albumin | 3.52 ± 0.67 g/dL (1.43−5.50) | 3.54 ± 0.73 g/dL (1.70−5.14) | 3.51 ± 0.61 g/dL (1.43−5.50) | 3.76 ± 0.46 g/dL (2.20−4.60) |
| β2 microglobulin | 5.17 ± 5.22 mg/L (0−62) | 5.11 ± 5.45 mg/L (0−62) | 5.20 ± 4.98 mg/L (0.15−43.40) | 2.25 ± 1.13 mg/L (0.30−4.41) |
| Hemoglobin | 10.54 ± 1.98 g/dL (4.90−15.60) | 10.55 ± 1.99 g/dL (5.50−15.50) | 10.56 ± 1.97 g/dL (4.90−15.60) | 12.38 ± 1.13 g/dL (10.10−14.70) |
| R-ISSa | ||||
| Stage I | 19.1% | 24.1% | 13.1% | 61.9% |
| Stage II | 69.7% | 62.8% | 77.9% | 38.1% |
| Stage III | 11.2% | 13.1% | 9.0% | 0% |
| ECOG | ||||
| 0 | 23.8% | 27.6% | 20.3% | 66.7% |
| 1 | 49.7% | 49.3% | 50.7% | 33.3% |
| 2 | 20.2% | 17.8% | 21.6% | 0% |
| 3 | 4.0% | 4.6% | 3.4% | 0% |
| 4 | 2.3% | 0.7% | 4.1% | 0% |
| Bone lesions | ||||
| None | 19.2% | 19.7% | 18.9% | 100% |
| Minor lesions | 42.1% | 45.4% | 38.5% | 0% |
| Major lesions | 38.7% | 34.9% | 42.7% | 0% |
| Plasmacytoma | 11.2% | 14.1% | 8.3% | 0% |
| High LDH | 15% | 16.6% | 13.3% | 5.4% |
| t(11;14) | 13.2% | 7.4% | 18.1% | 3.4% |
| t(4;14) | 11.7% | 12.2% | 9.4% | 19.4% |
| t(14;16) | 3% | 4.6% | 1% | 6.9% |
| 17p abnormalities | 7% | 7.1% | 7.2% | 4.3% |
| HR cytogenetics | 20.3% | 21.6% | 16.5% | 29.6% |
| 1q gain | 47.7% | 46.4% | 50% | 26.3% |
| del1p | 5.7% | 7.2% | 3% | 20% |
Clinical features were compared distinguishing between symptomatic (transplant-candidates and noncandidates) and smoldering myeloma patients.
IgH immunoglobulin heavy chain, IgL immunoglobulin light chain, R-ISS Revised International Staging System, ECOG Eastern Cooperative Oncology Group Performance Status, LDH lactate dehydrogenase, HR cytogenetics high-risk cytogenetics.
aProportions of each ISS group are shown instead of the R-ISS for asymptomatic myeloma patients.